Latest:
Series Wrap-up: Novel Therapies for mRCC
A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Thomas Helleday, PhD
Latest:
Similarity of Biosimilars and Biologics
Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.
Thomas J. Herzog, MD
Latest:
Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs
Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.
Thomas Herzog, MD, University of Cincinnati
Latest:
Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers
Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.